Nothing Special   »   [go: up one dir, main page]

Yuan et al., 2021 - Google Patents

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Yuan et al., 2021

View HTML
Document ID
4430396813600903738
Author
Yuan S
Yin X
Meng X
Chan J
Ye Z
Riva L
Pache L
Chan C
Lai P
Chan C
Poon V
Lee A
Matsunaga N
Pu Y
Yuen C
Cao J
Liang R
Tang K
Sheng L
Du Y
Xu W
Lau C
Sit K
Au W
Wang R
Zhang Y
Tang Y
Clausen T
Pihl J
Oh J
Sze K
Zhang A
Chu H
Kok K
Wang D
Cai X
Esko J
Hung I
Li R
Chen H
Sun H
Jin D
Sun R
Chanda S
Yuen K
Publication year
Publication venue
Nature

External Links

Snippet

The COVID-19 pandemic is the third outbreak this century of a zoonotic disease caused by a coronavirus, following the emergence of severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) in 2012. Treatment options for coronaviruses …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Yuan et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
Teng et al. Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12
Chen et al. COVID-19 infection: the China and Italy perspectives
Gamage et al. Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles
Hu et al. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
Lechowicz et al. COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection
Yuan et al. Broad-spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19)
Chen et al. AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling
Blaess et al. COVID-19/SARS-CoV-2 infection: lysosomes and lysosomotropism implicate new treatment strategies and personal risks
Park et al. Potential therapeutic effect of micrornas in extracellular vesicles from mesenchymal stem cells against SARS-CoV-2
Moazzam et al. Understanding COVID-19: from origin to potential therapeutics
Botwina et al. Berberine hampers influenza a replication through inhibition of MAPK/ERK pathway
Yuan et al. Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters
Logue et al. PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19
Airo et al. Flavivirus capsid proteins inhibit the interferon response
Wang et al. Isobavachalcone inhibits post-entry stages of the porcine reproductive and respiratory syndrome virus life cycle
Duan et al. Identification of drugs blocking SARS-CoV-2 infection using human pluripotent stem cell-derived colonic organoids
Tong et al. Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions
Liu et al. Ergosterol peroxide inhibits porcine epidemic diarrhea virus infection in vero cells by suppressing ROS generation and p53 activation
Chable-Bessia et al. Low selectivity indices of ivermectin and macrocyclic lactones on SARS-CoV-2 replication in vitro
Fang et al. Fucoidan-mediated inhibition of fibrotic properties in oral submucous fibrosis via the MEG3/miR-181a/Egr1 axis
Karuppan et al. Reduced-Beclin1-expressing mice infected with Zika-R103451 and viral-associated pathology during pregnancy
Shin et al. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation
Ramón et al. Targeting of protein kinase CK2 elicits antiviral activity on bovine coronavirus infection
Oliveira et al. ZIKV strains elicit different inflammatory and anti-viral responses in microglia cells